109 related articles for article (PubMed ID: 10432405)
1. Serum and urinary concentrations of heparan sulfate in patients with diabetic nephropathy.
Yokoyama H; Sato K; Okudaira M; Morita C; Takahashi C; Suzuki D; Sakai H; Iwamoto Y
Kidney Int; 1999 Aug; 56(2):650-8. PubMed ID: 10432405
[TBL] [Abstract][Full Text] [Related]
2. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane.
Tamsma JT; van den Born J; Bruijn JA; Assmann KJ; Weening JJ; Berden JH; Wieslander J; Schrama E; Hermans J; Veerkamp JH
Diabetologia; 1994 Mar; 37(3):313-20. PubMed ID: 8174847
[TBL] [Abstract][Full Text] [Related]
3. Extracellular matrix in human diabetic nephropathy: reduced expression of heparan sulphate in skin basement membrane.
van der Pijl JW; Daha MR; van den Born J; Verhagen NA; Lemkes HH; Bucala R; Berden JH; Zwinderman AH; Bruijn JA; van Es LA; van der Woude FJ
Diabetologia; 1998 Jul; 41(7):791-8. PubMed ID: 9686920
[TBL] [Abstract][Full Text] [Related]
4. Heparan sulfate analysis from diabetic rat glomeruli.
Lauer ME; Hascall VC; Wang A
J Biol Chem; 2007 Jan; 282(2):843-52. PubMed ID: 17038308
[TBL] [Abstract][Full Text] [Related]
5. Developmental changes in heparan sulfate expression: in situ detection with mAbs.
David G; Bai XM; Van der Schueren B; Cassiman JJ; Van den Berghe H
J Cell Biol; 1992 Nov; 119(4):961-75. PubMed ID: 1385449
[TBL] [Abstract][Full Text] [Related]
6. No change in glomerular heparan sulfate structure in early human and experimental diabetic nephropathy.
van den Born J; Pisa B; Bakker MA; Celie JW; Straatman C; Thomas S; Viberti GC; Kjellen L; Berden JH
J Biol Chem; 2006 Oct; 281(40):29606-13. PubMed ID: 16885165
[TBL] [Abstract][Full Text] [Related]
7. Early increase of chondroitin sulfate glycosaminoglycan in the glomerular basement membrane of rats with diabetic glomerulopathy.
Karasawa R; Nishi S; Suzuki Y; Imai N; Arakawa M
Nephron; 1997; 76(1):62-71. PubMed ID: 9171302
[TBL] [Abstract][Full Text] [Related]
8. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria.
Raats CJ; Van Den Born J; Berden JH
Kidney Int; 2000 Feb; 57(2):385-400. PubMed ID: 10652015
[TBL] [Abstract][Full Text] [Related]
9. [Expression of glomerular heparan sulfate domains in pediatric patients with minimal change nephrotic syndrome].
Dong LQ; Wang Z; Yu P; Guo YN; Wu J; Feng SP; Li S
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 40(1):55-8. PubMed ID: 19292045
[TBL] [Abstract][Full Text] [Related]
10. Heparan sulfate staining of the glomerular basement membrane in relation to circulating anti-DNA and anti-heparan sulfate reactivity: a longitudinal study in NZB/W F1 mice.
Hylkema MN; van Bruggen MC; van de Lagemaat R; Kramers K; Berden JH; Smeenk RJ
J Autoimmun; 1996 Feb; 9(1):41-50. PubMed ID: 8845053
[TBL] [Abstract][Full Text] [Related]
11. N-Acetylated domains in heparan sulfates revealed by a monoclonal antibody against the Escherichia coli K5 capsular polysaccharide. Distribution of the cognate epitope in normal human kidney and transplant kidney with chronic vascular rejection.
Born J; Jann K; Assmann KJ; Lindahl U; Berden JH
J Biol Chem; 1996 Sep; 271(37):22802-9. PubMed ID: 8798457
[TBL] [Abstract][Full Text] [Related]
12. Decreased glomerular expression of agrin in diabetic nephropathy and podocytes, cultured in high glucose medium.
Yard BA; Kahlert S; Engelleiter R; Resch S; Waldherr R; Groffen AJ; van den Heuvel LP; van der Born J; Berden JH; Kröger S; Hafner M; van der Woude FJ
Exp Nephrol; 2001; 9(3):214-22. PubMed ID: 11340306
[TBL] [Abstract][Full Text] [Related]
13. Novel heparan sulfate structures revealed by monoclonal antibodies.
van den Born J; Salmivirta K; Henttinen T; Ostman N; Ishimaru T; Miyaura S; Yoshida K; Salmivirta M
J Biol Chem; 2005 May; 280(21):20516-23. PubMed ID: 15778504
[TBL] [Abstract][Full Text] [Related]
14. Anti-heparan sulfate antibody and functional loss of glomerular heparan sulfate proteoglycans in lupus nephritis.
Kim HJ; Hong YH; Kim YJ; Kim HS; Park JW; Do JY; Kim KJ; Bae SW; Kim CW; Lee CK
Lupus; 2017 Jul; 26(8):815-824. PubMed ID: 28420046
[TBL] [Abstract][Full Text] [Related]
15. Production and characterization of a monoclonal antibody against human glomerular heparan sulfate.
van den Born J; van den Heuvel LP; Bakker MA; Veerkamp JH; Assmann KJ; Berden JH
Lab Invest; 1991 Sep; 65(3):287-97. PubMed ID: 1890809
[TBL] [Abstract][Full Text] [Related]
16. Heparan sulfate proteoglycans are lost in patients with diabetic nephropathy.
Makino H; Ikeda S; Haramoto T; Ota Z
Nephron; 1992; 61(4):415-21. PubMed ID: 1501738
[TBL] [Abstract][Full Text] [Related]
17. Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin.
Lewis EJ; Xu X
Diabetes Care; 2008 Feb; 31 Suppl 2():S202-7. PubMed ID: 18227486
[TBL] [Abstract][Full Text] [Related]
18. Urinary glycosaminoglycan excretion in NIDDM subjects: its relationship to albuminura.
McAuliffe AV; Fisher EJ; McLennan SV; Yue DK; Turtle JR
Diabet Med; 1996 Aug; 13(8):758-63. PubMed ID: 8862953
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of heparanase in overt diabetic nephropathy.
van den Hoven MJ; Rops AL; Bakker MA; Aten J; Rutjes N; Roestenberg P; Goldschmeding R; Zcharia E; Vlodavsky I; van der Vlag J; Berden JH
Kidney Int; 2006 Dec; 70(12):2100-8. PubMed ID: 17051139
[TBL] [Abstract][Full Text] [Related]
20. Ultrastructural changes of extracellular matrices in diabetic nephropathy revealed by high resolution scanning and immunoelectron microscopy.
Makino H; Yamasaki Y; Haramoto T; Shikata K; Hironaka K; Ota Z; Kanwar YS
Lab Invest; 1993 Jan; 68(1):45-55. PubMed ID: 8423676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
